ClinicalTrials.gg
CompletedNCT04650555Updated May 3, 2024Results posted

BIO 300 Oral Powder Safety and Pharmacokinetics

A Phase 1 interventional study of BIO 300 Oral Powder in Acute Radiation Syndrome, sponsored by Humanetics Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-03.

Sponsored by Humanetics Corporation · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

Open-label, single ascending dose and multiple single dose study in healthy volunteers to evaluate the safety and pharmacokinetics of BIO 300 Oral Powder (BIO 300). The single ascending dose study consists of 4 ascending dose cohorts and the multiple single dose study consists of a single dose given daily for 6 consecutive days.

02

Conditions studied

  • Acute Radiation Syndrome
03

In context

Lead sponsor

Humanetics Corporation is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult non-smokers, 18-64 years old.
  2. 18-32 kg/m\^2.
  3. No ingestion of prescription or over-the-counter medications (including dietary and herbal supplements) for 7 days prior to first dose of study drug and no planned use during study participation. Acetaminophen of up to 3 g/day and ibuprofen up to 1 g/day will be allowed at discretion of the Investigator.
  4. At the discretion of the Investigator, blood routine, liver and kidney functions are within the controllable range.

    1. Adequate hepatic function as evidenced by , AST or LDH \< 1.25X and \< 1.5X ULN for the reference lab.
    2. Adequate renal function as evidenced by a serum creatinine ≤ 1.5 X ULN for the reference laboratory OR a calculated of ≥ 60 mL/min by the Cockcroft-Gault Equation.
    3. Adequate hematopoietic function as evidenced by white blood cells ≥ 3x10\^9 / L and ≥ 100x10\^9 / L.
  5. Female subjects of must have a negative pregnancy test within 72 hours of the start of treatment.
  6. Subjects must agree to abstain from heterosexual intercourse or use a reliable method of for 7 days after their last dose. Subjects using hormonal contraception are required to utilize condom/spermicide + additional barrier method for 7 days after their last dose.
  7. Ability to read and provide written .
  8. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, dietary restrictions, and other study procedures.
  9. No abnormalities identified by medical history, physical examination, vital signs, , and clinical laboratory tests in the opinion of the Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Any prior use of the study test article.
  2. Any weight loss any time in prior 4 weeks at discretion of Investigator based on medical history interview.
  3. Subjects with any of the following are not eligible;

    1. Previous history of prolongation resulting from "known-risk" medications (www.Crediblemeds.org) that required discontinuation of that medication;
    2. Congenital long QT syndrome, or 1st degree relative with unexplained sudden death under 40 years of age;
    3. Presence of left bundle branch block (LBBB);
    4. QTc with Fridericia's correction (QTcF) that is unmeasurable, or ≥ 480 msec on screening . The average QTcF from the screening ECG (completed in triplicate) must be \< 480 msec in order for the subject to be eligible for the study.
  4. Subjects must not have had a clinically significant cardiac event such as myocardial infarction (within 6 months prior to the first dose of the study treatment); uncontrolled/symptomatic congestive heart failure ( (NYHA) classification of heart disease, Class III or IV, see Appendix 3) within 6 months before entry; or the presence of any other uncontrolled cardiovascular conditions [unstable hypertension at discretion of Investigator or arrhythmia, unstable angina pectoris, or severe valvular heart disease, etc.] that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
  5. Subjects with a history of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) which is symptomatic or requires treatment ( Grade 3) or asymptomatic sustained ventricular tachycardia are not eligible. Subjects with atrial fibrillation with well-controlled ventricular rate are eligible at the discretion of the Investigator.
  6. Psychiatric conditions, social situations or substance abuse that precludes the ability of the subject to cooperate with the requirements of the trial and protocol therapy at Investigator discretion.
  7. Inability to refrain from alcohol consumption for 48 hours prior to day 1 and for the duration of the study. Illicit drugs, including THC, must be avoided from screen through the duration of the study.
  8. Grade 2 or higher peripheral neuropathy.
  9. Positive results for Hep B surface antigen, Hep C antibody, or 1/2 antibody at screening visit.
  10. Clinically significant immunodeficiency disorder in the opinion of the Investigator.
  11. Pregnancy or women of and men who are sexually active and not willing/able to use medically acceptable forms of .
  12. Women who are breastfeeding are not eligible for this study.
  13. Subjects that are vegan, vegetarian or consume a soy-rich diet.
  14. Any history of systemic infection requiring hospitalization, systemic antibiotics, or as judged clinically significant by the investigator in the 3 months prior to day 1.
  15. Any condition possibly affecting drug absorption (e.g., prior bariatric surgery, gastrectomy, intestinal resection). Participants who have undergone appendectomy or cholecystectomy are allowed so long as the surgery occurred more than 6 months prior to day 1.
  16. Treatment with another drug within 30 days or 5 half-lives (whichever is longer) proceeding Day 1.
  17. Positive drug screen or alcohol test at screen and day 1 predose.
  18. Blood donation of approximately 1 pint (500 ml) or more within 60 days of day 1; plasma donations within 14 days of day 1. Subjects must agree not to donate blood or plasma for the duration of the study and for 30 days following end of study procedures.
  19. Inability to swallow powdered medication followed with water.
  20. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  21. Considered by the Investigator to be unsuitable to participate in the study for any other reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose Cohort 1

    500 mg BIO 300 Oral Powder administered as a single dose

    Drug: BIO 300 Oral Powder

  • Experimental
    Single Ascending Dose Cohort 2

    1000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose

    Drug: BIO 300 Oral Powder

  • Experimental
    Single Ascending Dose Cohort 3

    2000 mg BIO 300 Oral Powder, if dose escalation criteria met, administered as a single dose

    Drug: BIO 300 Oral Powder

  • Experimental
    Single Ascending Dose Cohort 4

    Single dose to be determined based on the safety and pharmacokinetic profiles in cohorts 1-3

    Drug: BIO 300 Oral Powder

  • Experimental
    Multiple Single Dose Cohort 5

    Highest dose or maximum tolerated dose from the Single Ascending Dose study administered as a single dose given daily for 6 consecutive days

    Drug: BIO 300 Oral Powder

Interventions

  • Amorphous solid dispersion of genistein milled into a powder

    Also known as: BIO 300, Genistein

06

What researchers measure

Primary outcomes

  1. Adverse Events Related to BIO 300 Oral Powder

    Evaluate the safety of single and multiple dose BIO 300 Oral Powder administration

    Time frame: Day 1 up to 1 week for Single Ascending Dose and Day 1 up to 2 weeks for Multiple Single Dose

  2. Change in ECG QTc Interval

    Measurement of the average QTc interval with Fridericia's correction (completed in triplicate at each timepoint)

    Time frame: Day 1 up to 1 week after the last dose for Single Ascending Dose and Multiple Single Dose Cohorts

  3. Change in Clinical Laboratory Values

    Monitoring of blood serum levels of albumin and total protein (all reported as g/dL)

    Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose

  4. Change in Clinical Laboratory Values

    Monitoring of blood serum levels of bicarbonate, chloride, potassium, and sodium (all reported as mEq/L)

    Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose

  5. Change in Clinical Laboratory Values

    Monitoring of blood serum levels of bilirubin (total and direct), BUN, calcium, cholesterol (total), creatinine, HDL, glucose, magnesium, phosphorous, triglycerides, and uric acid (all reported as mg/dL)

    Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose

  6. Change in Clinical Laboratory Values

    Monitoring of blood serum levels of alkaline phosphatase, ALT, amylase, AST, LDH, and lipase (all reported as IU/L)

    Time frame: Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose

  7. Area Under Curve of Genistein-Aglycone in Serum

    Area under the curve of BIO 300 Oral Powder as assessed by analyzing serum concentrations of genistein-aglycone (free genistein) at multiple timepoints

    Time frame: Day 1 for the Single Ascending Dose and Day 6 for the Multiple Single Dose, prior to 1st dose then 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post dose and Day 1 Multiple Single Dose prior to dosing then 0.5, 1, 2, and 4 hours post dose

Secondary outcomes

  1. Number of Differentially Expressed Genes From Whole Blood Samples

    The number of significantly differentially expressed genes detected in whole blood samples at various timepoints after BIO 300 Oral Powder dosing. Significant differential gene expression was defined as genes that have a mean absolute log2 fold change \>2 with an adjusted p-value of \<0.05 relative to baseline expression levels.

    Time frame: Day 1 for the Single Ascending Dose prior to dosing then 1, 2, 4, and 24 hours post dose and Day 1 Multiple Single Dose prior to dosing then 1, 2, and 4 hours post dose and and Day 6 prior to dosing then 4, 8, 12 and 24 hours post dose

07

Results

Posted May 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Started666610
Completed66568
Not completed00102

Outcome measures

PrimaryAdverse Events Related to BIO 300 Oral Powder

Evaluate the safety of single and multiple dose BIO 300 Oral Powder administration

Time frame:
Day 1 up to 1 week for Single Ascending Dose and Day 1 up to 2 weeks for Multiple Single Dose
Reported as:
Number · Number of Adverse Events
Adverse Events Related to BIO 300 Oral Powder
Number of Adverse EventsSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Dose Limiting Toxicities—0000
Unlikely Treatment-Related Adverse Events—1002
Possibly Treatment-Related Adverse Events—0037
Probably Treatment-Related Adverse Events—44015
Definitely Treatment-Related Adverse Events—0021
Unrelated Adverse Event—0011
PrimaryChange in ECG QTc Interval

Measurement of the average QTc interval with Fridericia's correction (completed in triplicate at each timepoint)

Time frame:
Day 1 up to 1 week after the last dose for Single Ascending Dose and Multiple Single Dose Cohorts
Reported as:
Mean · milliseconds
Change in ECG QTc Interval
millisecondsSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Screening407 ± 9.3402 ± 19.3416 ± 21.8415 ± 18.7413 ± 13.3
4 Hours Post First Dose412 ± 9.6407 ± 16.5419 ± 27.8420 ± 16.3417 ± 7.4
24 Hours Post First Dose407 ± 11.3400 ± 11.2402 ± 26.7404 ± 41.7413 ± 9.9
1 Week Post Last Dose408 ± 12.4401 ± 18.3416 ± 36.3414 ± 12.6415 ± 9.0
PrimaryChange in Clinical Laboratory Values

Monitoring of blood serum levels of albumin and total protein (all reported as g/dL)

Time frame:
Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Reported as:
Mean · g/dL
Change in Clinical Laboratory Values
g/dLSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Albumin Day 34.483 ± 0.2044.433 ± 0.3934.333 ± 0.3674.550 ± 0.1874.225 ± 0.349
Albumin Day 6————4.475 ± 0.249
Albumin Day 74.233 ± 0.2164.283 ± 0.2794.440 ± 0.2414.517 ± 0.117—
Albumin Day 13————4.475 ± 0.306
Total Protein Day 36.667 ± 0.3446.833 ± 0.6386.500 ± 0.3696.650 ± 0.5476.363 ± 0.444
Total Protein Day 6————6.788 ± 0.348
Total Protein Day 76.417 ± 0.3316.850 ± 0.6196.520 ± 0.4386.717 ± 0.454—
Total Protein Day 13————6.550 ± 0.518
PrimaryChange in Clinical Laboratory Values

Monitoring of blood serum levels of bicarbonate, chloride, potassium, and sodium (all reported as mEq/L)

Time frame:
Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Reported as:
Mean · mEq/L
Change in Clinical Laboratory Values
mEq/LSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Bicarbonate Day 326.833 ± 1.72226.167 ± 0.75327.167 ± 2.40127.500 ± 1.04923.875 ± 2.850
Bicarbonate Day 6————23.750 ± 1.165
Bicarbonate Day 726.500 ± 1.87127.500 ± 1.76129.000 ± 0.70728.667 ± 1.751—
Bicarbonate Day 13————23.125 ± 1.246
Chloride Day 3104.5 ± 2.429104.0 ± 1.549104.7 ± 0.816103.5 ± 0.837105.5 ± 1.927
Chloride Day 6————103.8 ± 2.252
Chloride Day 7104.3 ± 1.366104.5 ± 1.761104.2 ± 1.095104.8 ± 2.317—
Chloride Day 13————105.1 ± 0.835
Potassium Day 34.417 ± 0.2714.500 ± 0.1414.617 ± 0.3064.400 ± 0.3034.288 ± 0.318
Potassium Day 6————4.413 ± 0.336
Potassium Day 74.217 ± 0.2794.483 ± 0.3064.580 ± 0.4604.233 ± 0.151—
Potassium Day 13————4.288 ± 0.155
Sodium Day 3140.7 ± 1.966139.5 ± 1.225140.7 ± 0.816140.2 ± 1.835140.0 ± 1.414
Sodium Day 6————139.5 ± 1.414
Sodium Day 7140.0 ± 1.265139.2 ± 1.472139.2 ± 1.304142.3 ± 2.066—
Sodium Day 13————140.1 ± 1.727
PrimaryChange in Clinical Laboratory Values

Monitoring of blood serum levels of bilirubin (total and direct), BUN, calcium, cholesterol (total), creatinine, HDL, glucose, magnesium, phosphorous, triglycerides, and uric acid (all reported as mg/dL)

Time frame:
Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Reported as:
Mean · mg/dL
Change in Clinical Laboratory Values
mg/dLSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Total Bilirubin Day 30.467 ± 0.3080.417 ± 0.1170.333 ± 0.1370.650 ± 0.5010.613 ± 0.394
Total Bilirubin Day 6————0.500 ± 0.185
Total Bilirubin Day 70.483 ± 0.3310.583 ± 0.4170.340 ± 0.1670.400 ± 0.141—
Total Bilirubin Day 13————0.563 ± 0.307
Direct Bilirubin Day 30.200 ± 00.200 ± 00.200 ± 00.200 ± 00.200 ± 0
Direct Bilirubin Day 6————0.200 ± 0
Direct Bilirubin Day 70.200 ± 00.200 ± 00.200 ± 00.200 ± 0—
Direct Bilirubin Day 13————0.200 ± 0
BUN Day 318.00 ± 3.4613.33 ± 2.9414.83 ± 4.6213.50 ± 4.5111.88 ± 3.09
BUN Day 6————12.00 ± 2.83
BUN Day 716.67 ± 4.2314.50 ± 2.8814.20 ± 5.8513.83 ± 4.26—
BUN Day 13————11.63 ± 3.82
Calcium Day 39.73 ± 0.379.38 ± 0.329.27 ± 0.239.72 ± 0.339.25 ± 0.34
Calcium Day 6————9.60 ± 0.19
Calcium Day 79.47 ± 0.149.37 ± 0.269.18 ± 0.379.50 ± 0.32—
Calcium Day 13————9.36 ± 0.30
Cholesterol Day 3200 ± 43181 ± 23158 ± 19210 ± 44178 ± 23
Cholesterol Day 6————193 ± 22
Cholesterol Day 7195 ± 34180 ± 33173 ± 32213 ± 49—
Cholesterol Day 13————177 ± 26
Creatinine Day 30.905 ± 0.1820.943 ± 0.1540.883 ± 0.1800.900 ± 0.1270.944 ± 0.116
Creatinine Day 6————1.030 ± 0.099
Creatinine Day 70.873 ± 0.1471.028 ± 0.1500.954 ± 0.2120.980 ± 0.131—
Creatinine Day 13————1.043 ± 0.094
HDL Day 352 ± 1155 ± 1552 ± 1069 ± 2149 ± 14
HDL Day 6————55 ± 15
HDL Day 752 ± 954 ± 1656 ± 971 ± 23—
HDL Day 13————52 ± 17
Glucose Day 395.2 ± 8.089.7 ± 7.390.7 ± 6.590.2 ± 8.896.3 ± 5.8
Glucose Day 6————93.6 ± 5.2
Glucose Day 7101.5 ± 10.092.3 ± 2.797.0 ± 12.1105.8 ± 40.8—
Glucose Day 13————93.4 ± 4.7
Magnesium Day 32.10 ± 0.112.05 ± 0.142.07 ± 0.121.90 ± 0.171.98 ± 0.10
Magnesium Day 6————2.05 ± 0.17
Magnesium Day 72.02 ± 0.122.12 ± 0.102.06 ± 0.111.98 ± 0.12—
Magnesium Day 13————2.06 ± 0.09
Phosphorous Day 33.58 ± 0.373.62 ± 0.453.75 ± 0.413.52 ± 0.343.14 ± 0.36
Phosphorous Day 6————3.49 ± 0.34
Phosphorous Day 73.62 ± 0.533.68 ± 0.423.70 ± 0.493.68 ± 0.62—
Phosphorous Day 13————0.39 ± 0.54
Triglycerides Day 380.2 ± 43.3104.2 ± 91.080.5 ± 37.585.5 ± 30.6101.9 ± 38.8
Triglycerides Day 6————98.6 ± 23.3
Triglycerides Day 771.3 ± 22.1117.3 ± 107.079.2 ± 44.580.5 ± 39.7—
Triglycerides Day 13————89.8 ± 20.6
Uric Acid Day 35.25 ± 1.084.62 ± 1.264.48 ± 1.165.07 ± 1.385.20 ± 1.50
Uric Acid Day 6————5.21 ± 1.55
Uric Acid Day 75.13 ± 1.095.30 ± 1.894.10 ± 0.735.08 ± 1.24—
Uric Acid Day 13————5.20 ± 1.60
PrimaryChange in Clinical Laboratory Values

Monitoring of blood serum levels of alkaline phosphatase, ALT, amylase, AST, LDH, and lipase (all reported as IU/L)

Time frame:
Day 3 and 7 for Single Ascending Dose and Day 3, 6 and 13 for Multiple Single Dose
Reported as:
Mean · IU/L
Change in Clinical Laboratory Values
IU/LSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
ALP Day 374.2 ± 18.166.7 ± 13.964.2 ± 18.862.8 ± 21.459.5 ± 15.5
ALP Day 6————60.3 ± 16.2
ALP Day 769.5 ± 14.769.0 ± 17.368.0 ± 21.152.5 ± 29.7—
ALP Day 13————59.4 ± 18.6
ALT Day 318.2 ± 5.721.2 ± 18.615.2 ± 3.216.2 ± 9.517.6 ± 5.5
ALT Day 6————18.4 ± 4.1
ALT Day 716.7 ± 3.927.8 ± 24.117.8 ± 6.316.7 ± 10.7—
ALT Day 13————18.1 ± 5.1
Amylase Day 326.5 ± 8.032.2 ± 13.721.8 ± 8.726.8 ± 8.028.0 ± 7.9
Amylase Day 6————32.8 ± 10.1
Amylase Day 725.8 ± 7.330.3 ± 13.422.6 ± 10.126.8 ± 10.5—
Amylase Day 13————29.8 ± 8.8
AST Day 319.0 ± 3.619.7 ± 6.021.2 ± 6.421.8 ± 6.117.8 ± 3.7
AST Day 6————19.6 ± 4.3
AST Day 719.2 ± 3.726.3 ± 11.923.6 ± 10.922.2 ± 6.1—
AST Day 13————18.1 ± 5.1
LDH Day 3170 ± 20147 ± 14152 ± 31171 ± 48158 ± 15
LDH Day 6————166 ± 19
LDH Day 7171 ± 22157 ± 27161 ± 17179 ± 39—
LDH Day 13————173 ± 21
Lipase Day 326.2 ± 4.942.8 ± 31.923.8 ± 10.733.3 ± 10.628.6 ± 8.4
Lipase Day 6————35.5 ± 13.6
Lipase Day 726.8 ± 3.935.8 ± 10.526.6 ± 13.632.0 ± 13.3—
Lipase Day 13————31.4 ± 9.3
PrimaryArea Under Curve of Genistein-Aglycone in Serum

Area under the curve of BIO 300 Oral Powder as assessed by analyzing serum concentrations of genistein-aglycone (free genistein) at multiple timepoints

Time frame:
Day 1 for the Single Ascending Dose and Day 6 for the Multiple Single Dose, prior to 1st dose then 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 hours post dose and Day 1 Multiple Single Dose prior to dosing then 0.5, 1, 2, and 4 hours post dose
Reported as:
Mean · ng/mL*hr
Area Under Curve of Genistein-Aglycone in Serum
ng/mL*hrSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Area Under Curve of Genistein-Aglycone in Serum902.9 ± 605.11530.9 ± 518.21730.8 ± 361.65836.0 ± 3280.82957.3 ± 1222.4
SecondaryNumber of Differentially Expressed Genes From Whole Blood Samples

The number of significantly differentially expressed genes detected in whole blood samples at various timepoints after BIO 300 Oral Powder dosing. Significant differential gene expression was defined as genes that have a mean absolute log2 fold change \>2 with an adjusted p-value of \<0.05 relative to baseline expression levels.

Time frame:
Day 1 for the Single Ascending Dose prior to dosing then 1, 2, 4, and 24 hours post dose and Day 1 Multiple Single Dose prior to dosing then 1, 2, and 4 hours post dose and and Day 6 prior to dosing then 4, 8, 12 and 24 hours post dose
Reported as:
Number · Differentially expressed genes
Number of Differentially Expressed Genes From Whole Blood Samples
Differentially expressed genesSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
Day 1, 1 hr post-dose0—000
Day 1, 2 hr post-dose0—000
Day 1, 4 hr post-dose0—100
Day 1, 24 hr post-dose0—000
Day 6, 4 hr post-dose0—000
Day 6, 8 hr post-dose0—006
Day 6, 12 hr post-dose0—007
Day 6, 24 hr post-dose0—000

Adverse events

Collected over Screening to 1 week after the last dose of BIO 300 Oral Powder (up to 5 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Single Ascending Dose Cohort 10/6 (0%)0/6 (0%)0/6 (0%)
Single Ascending Dose Cohort 20/6 (0%)0/6 (0%)4/6 (66.7%)
Single Ascending Dose Cohort 30/6 (0%)0/6 (0%)2/6 (33.3%)
Single Ascending Dose Cohort 40/6 (0%)0/6 (0%)5/6 (83.3%)
Multiple Single Dose Cohort 50/10 (0%)0/10 (0%)8/10 (80%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventSingle Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5
HeadacheNervous system disorders0/63/62/64/64/10
DiarrheaGastrointestinal disorders0/61/60/61/66/10
ConstipationGastrointestinal disorders0/60/62/60/60/10
FatigueGeneral disorders0/60/60/60/63/10
NauseaGastrointestinal disorders0/60/60/61/62/10
MyalgiaMusculoskeletal and connective tissue disorders0/60/60/60/62/10
Lipase IncreasedInvestigations0/61/60/60/60/10
PalpitationsCardiac disorders0/60/60/60/61/10
Abdominal PainGastrointestinal disorders0/60/60/60/61/10
BloatingGastrointestinal disorders0/60/60/60/61/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Single Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5Total
Median55 (27 to 59)37 (28 to 58)40 (22 to 62)48 (19 to 63)46 (22 to 65)45 (19 to 65)
Sex: Female, Male
Sex: Female, Male(Participants)Single Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5Total
Female4333518
Male2333516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Single Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5Total
Hispanic or Latino100001
Not Hispanic or Latino56661033
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5Total
American Indian or Alaska Native000000
Asian100113
Native Hawaiian or Other Pacific Islander000000
Black or African American001012
White5655829
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Single Ascending Dose Cohort 1Single Ascending Dose Cohort 2Single Ascending Dose Cohort 3Single Ascending Dose Cohort 4Multiple Single Dose Cohort 5Total
United States66661034
08

Study locations

1 site
  • Nucleus Network, Ltd (Formally Prism Research, LLC)
    Saint Paul, Minnesota 55114, United States
09

References and documents

Publications

  • Serebrenik AA, Verduyn CW, Kaytor MD. Safety, Pharmacokinetics, and Biomarkers of an Amorphous Solid Dispersion of Genistein, a Radioprotectant, in Healthy Volunteers. Clin Pharmacol Drug Dev. 2023 Feb;12(2):190-201. doi: 10.1002/cpdd.1188. Epub 2022 Oct 27. PubMed 36301689 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jul 2021, 6 months.

Results were first posted in May 2024, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Dec 2, 2020
StartActual
Dec 8, 2020
Primary completionActual
Jul 6, 2021
CompletionActual
Jul 6, 2021
Results first posted
May 3, 2024
Last update
May 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04650555
Lead sponsor
Humanetics Corporation
Collaborators
United States Department of Defense, Joint Warfighter Medical Research Program
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Dec 8, 2020
Primary completion
Jul 6, 2021
Completion
Jul 6, 2021
Results posted
May 3, 2024
Last update
May 3, 2024

Study contacts

Michael D Kaytor, Ph.D.
principal investigator · Humanetics Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Genistein-based BIO 300

Start the discussion